BMS 599626 is a potent tyrosine kinase inhibitor belonging to the indazol class, engineered to target HER1 and HER2 receptors for the potential treatment of solid tumors, including non-small cell lung… Read more
BMS 599626 is a potent tyrosine kinase inhibitor belonging to the indazol class, engineered to target HER1 and HER2 receptors for the potential treatment of solid tumors, including non-small cell lung cancer and gastric cancer. By inhibiting these specific receptors, the compound disrupts essential signaling pathways responsible for tumor cell proliferation and survival. This collection provides pharmaceutical researchers and analytical chemists with the necessary materials for robust quality control and rigorous drug analysis. It includes high-quality reference standards of the parent drug, alongside its related pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. These materials are critical for accurate impurity profiling, supporting the development of precise analytical methods, and ensuring the reliability of validation studies throughout the drug manufacturing lifecycle. The availability of these standards facilitates compliance with regulatory requirements for characterizing complex chemical structures within pharmaceutical products.